Reported relationships
Latest disclosed role at each company.
| Company | Last reported as | Report date | Published |
|---|---|---|---|
| 60 DEGREES PHARMACEUTICALS, INC.SXTP · Entity 8389 | CFO | January 02, 2025 | January 24, 2025 |
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
60 DEGREES PHARMACEUTICALS, INC.
Report date January 02, 2025 · Filed January 24, 2025
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Stock Option (Right to Buy)SEC Table II · derivative / convertible security · Conversion / exercise price $1.31 · Expires 2030-01-02 | Direct | 75,000 |
Reported balance
After 2025-01-02 transaction · row 1
Instrument identity requires review; Table II rows are not merged.
1 source rowRow 1 · 2025-01-02 · Grant · Acquired 75,000 · Balance 75,000 F1: The stock options were fully vested as of January 2, 2025, the grant date. |
Filing footnotes · ownership attribution and instrument terms
F1: The stock options were fully vested as of January 2, 2025, the grant date.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| January 17, 2025 Filed Jan 21, 2025 21:58 UTC | 60 DEGREES PHARMACEUTICALS, INC. SXTP · Entity 8389 | GrantCommon Stock | 11,626 | $0.00 | $0.00 |
DisclosureSEC source: 0001213900-25-005051 · ownership.xml · nonDerivative · entry 1 MILLER TYRONE · CIK 0001976962 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 26,370 F1 · balance_after: Adjusted to reflect the Issuer's 1:12 reverse stock split on August 12, 2024. Read SEC document |
| January 02, 2025 Filed Jan 24, 2025 21:51 UTC | 60 DEGREES PHARMACEUTICALS, INC. SXTP · Entity 8389 | GrantStock Option (Right to Buy) · Derivative | 75,000 | $0.00 Strike: $1.31 | $0.00 |
DisclosureSEC source: 0001213900-25-006569 · ownership.xml · derivative · entry 1 MILLER TYRONE · CIK 0001976962 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires 2030-01-02 F1 · derivative.exercise_date: The stock options were fully vested as of January 2, 2025, the grant date. Read SEC document |
| May 16, 2024 Filed May 22, 2024 00:22 UTC | 60 DEGREES PHARMACEUTICALS, INC. SXTP · Entity 8389 | Exercise / conversionRestricted Stock Units · Derivative | 15,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-045707 · ownership.xml · derivative · entry 5 MILLER TYRONE · CIK 0001976962 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 15,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock. F5 · security: 15,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 15,000 RSUs, Tyrone Miller did not own any RSUs. F5 · shares: 15,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 15,000 RSUs, Tyrone Miller did not own any RSUs. F5 · derivative.exercise_date: 15,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 15,000 RSUs, Tyrone Miller did not own any RSUs. F5 · derivative.expiration_date: 15,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 15,000 RSUs, Tyrone Miller did not own any RSUs. F5 · derivative.underlying_shares: 15,000 shares underlying the RSUs were settled as of May 16, 2024. After the settlement of the shares of common stock that were underlying the 15,000 RSUs, Tyrone Miller did not own any RSUs. Read SEC document |
| May 16, 2024 Filed May 22, 2024 00:22 UTC | 60 DEGREES PHARMACEUTICALS, INC. SXTP · Entity 8389 | GrantCommon Stock | 15,000 | $0.22 | $3,345.00 |
DisclosureSEC source: 0001213900-24-045707 · ownership.xml · nonDerivative · entry 2 MILLER TYRONE · CIK 0001976962 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 176,928 F2 · security: 15,000 shares underlying the RSUs were settled on May 16, 2024 (the "5/24 Shares"). Tyrone Miller owned 161,928 shares of common stock immediately prior to the issuance of the 5/24 Shares. As of May 16, 2024, Tyrone Miller owned a total of 176,928 shares of common stock. F2 · shares: 15,000 shares underlying the RSUs were settled on May 16, 2024 (the "5/24 Shares"). Tyrone Miller owned 161,928 shares of common stock immediately prior to the issuance of the 5/24 Shares. As of May 16, 2024, Tyrone Miller owned a total of 176,928 shares of common stock. F2 · balance_after: 15,000 shares underlying the RSUs were settled on May 16, 2024 (the "5/24 Shares"). Tyrone Miller owned 161,928 shares of common stock immediately prior to the issuance of the 5/24 Shares. As of May 16, 2024, Tyrone Miller owned a total of 176,928 shares of common stock. Read SEC document |
| April 12, 2024 Filed May 22, 2024 00:22 UTC | 60 DEGREES PHARMACEUTICALS, INC. SXTP · Entity 8389 | Exercise / conversionRestricted Stock Units · Derivative | 60,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-045707 · ownership.xml · derivative · entry 4 MILLER TYRONE · CIK 0001976962 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 15,000 Underlying: Common Stock · 60,000 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock. F4 · security: 60,000 shares underlying the RSUs were settled on April 12, 2024. After the settlement of the shares of common stock that were underlying the 60,000 RSUs, Tyrone Miller owned a total of 15,000 RSUs. F4 · shares: 60,000 shares underlying the RSUs were settled on April 12, 2024. After the settlement of the shares of common stock that were underlying the 60,000 RSUs, Tyrone Miller owned a total of 15,000 RSUs. F4 · derivative.exercise_date: 60,000 shares underlying the RSUs were settled on April 12, 2024. After the settlement of the shares of common stock that were underlying the 60,000 RSUs, Tyrone Miller owned a total of 15,000 RSUs. F4 · derivative.expiration_date: 60,000 shares underlying the RSUs were settled on April 12, 2024. After the settlement of the shares of common stock that were underlying the 60,000 RSUs, Tyrone Miller owned a total of 15,000 RSUs. F4 · derivative.underlying_shares: 60,000 shares underlying the RSUs were settled on April 12, 2024. After the settlement of the shares of common stock that were underlying the 60,000 RSUs, Tyrone Miller owned a total of 15,000 RSUs. Read SEC document |
| April 12, 2024 Filed May 22, 2024 00:22 UTC | 60 DEGREES PHARMACEUTICALS, INC. SXTP · Entity 8389 | GrantCommon Stock | 60,000 | $0.27 | $16,008.00 |
DisclosureSEC source: 0001213900-24-045707 · ownership.xml · nonDerivative · entry 1 MILLER TYRONE · CIK 0001976962 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 161,928 F1 · security: Tyrone Miller was granted a total of 75,000 restricted stock units ("RSUs") on November 21, 2023 that were fully vested as of the grant date. 60,000 shares underlying the RSUs were settled on April 12, 2024 (the "4/24 Shares"). Tyrone Miller owned 101,928 shares of common stock immediately prior to the issuance of the 4/24 Shares. As of April 12, 2024, Tyrone Miller owned a total of 161,928 shares of common stock. F1 · shares: Tyrone Miller was granted a total of 75,000 restricted stock units ("RSUs") on November 21, 2023 that were fully vested as of the grant date. 60,000 shares underlying the RSUs were settled on April 12, 2024 (the "4/24 Shares"). Tyrone Miller owned 101,928 shares of common stock immediately prior to the issuance of the 4/24 Shares. As of April 12, 2024, Tyrone Miller owned a total of 161,928 shares of common stock. F1 · balance_after: Tyrone Miller was granted a total of 75,000 restricted stock units ("RSUs") on November 21, 2023 that were fully vested as of the grant date. 60,000 shares underlying the RSUs were settled on April 12, 2024 (the "4/24 Shares"). Tyrone Miller owned 101,928 shares of common stock immediately prior to the issuance of the 4/24 Shares. As of April 12, 2024, Tyrone Miller owned a total of 161,928 shares of common stock. Read SEC document |
| November 21, 2023 Filed May 22, 2024 00:22 UTC | 60 DEGREES PHARMACEUTICALS, INC. SXTP · Entity 8389 | GrantRestricted Stock Units · Derivative | 75,000 | $0.00 Strike: $0.00 | $0.00 |
DisclosureSEC source: 0001213900-24-045707 · ownership.xml · derivative · entry 3 MILLER TYRONE · CIK 0001976962 · CFO 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 75,000 Underlying: Common Stock · 75,000 shares Expires not disclosed F3 · security: Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock. F3 · shares: Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock. F3 · derivative.exercise_date: Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock. F3 · derivative.expiration_date: Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock. F3 · derivative.underlying_shares: Tyrone Miller was granted a total of 75,000 restricted stock units on November 21, 2023 that were fully vested as of the grant date. Each RSU represents the right to receive, at settlement, one share of common stock. Read SEC document |
| July 12, 2023 Filed Jul 12, 2023 18:54 UTC | 60 DEGREES PHARMACEUTICALS, INC. SXTP · Entity 8389 | GrantNon-Qualified Stock Options (right to buy) · Derivative | 240,000 | $0.00 Strike: $5.30 | $0.00 |
DisclosureSEC source: 0001575872-23-001135 · ownership.xml · derivative · entry 1 MILLER TYRONE · CIK 0001976962 · Chief Financial Officer 10b5-1 filing: No plan indicated Ownership: Direct Disclosed balance after: 240,000 Underlying: Common Stock · 240,000 shares Expires 2028-07-12 F1 · security: Non-Qualified Stock Option granted pursuant that certain Employment Agreement, dated January 1, 2023, between the Issuer and the Reporting Person, subject to terms and conditions of the Issuer's 2022 Equity Incentive Plan. F2 · shares: Vests in 12,000 increments on the last day of each fiscal quarter (March 31st, June 30th, September 30th, December 31st). F3 · derivative.exercise_date: Date indicated is the date of grant. F2 · derivative.underlying_shares: Vests in 12,000 increments on the last day of each fiscal quarter (March 31st, June 30th, September 30th, December 31st). Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.